Product
Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine
1 clinical trial
8 indications
Indication
TislelizumabIndication
BevacizumabIndication
OxaliplatinIndication
CapecitabineIndication
MSS/pMMRIndication
Metastatic Colorectal CancerIndication
RAS-mutatedIndication
First-LineClinical trial
XELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS/pMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study.Status: Recruiting, Estimated PCD: 2025-07-01